Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma

Adil I. Daud, Kimberly Loo, Mariela L. Pauli, Robert Sanchez-Rodriguez, Priscila Munoz Sandoval, Keyon Taravati, Katy Tsai, Adi Nosrati, Lorenzo Nardo, Michael D. Alvarado, Alain P. Algazi, Miguel H. Pampaloni, Iryna V. Lobach, Jimmy Hwang, Robert H. Pierce, Iris K. Gratz, Matthew F. Krummel, Michael D. Rosenblum

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS. We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS. Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS. Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.

Original languageEnglish (US)
Pages (from-to)3447-3452
Number of pages6
JournalJournal of Clinical Investigation
Volume126
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Melanoma
Neoplasms
T-Lymphocytes
Therapeutics
Phenotype
Granzymes
T-Lymphocyte Subsets
Disease-Free Survival
Flow Cytometry
Cell Death
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., ... Rosenblum, M. D. (2016). Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. Journal of Clinical Investigation, 126(9), 3447-3452. https://doi.org/10.1172/JCI87324

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. / Daud, Adil I.; Loo, Kimberly; Pauli, Mariela L.; Sanchez-Rodriguez, Robert; Sandoval, Priscila Munoz; Taravati, Keyon; Tsai, Katy; Nosrati, Adi; Nardo, Lorenzo; Alvarado, Michael D.; Algazi, Alain P.; Pampaloni, Miguel H.; Lobach, Iryna V.; Hwang, Jimmy; Pierce, Robert H.; Gratz, Iris K.; Krummel, Matthew F.; Rosenblum, Michael D.

In: Journal of Clinical Investigation, Vol. 126, No. 9, 01.09.2016, p. 3447-3452.

Research output: Contribution to journalArticle

Daud, AI, Loo, K, Pauli, ML, Sanchez-Rodriguez, R, Sandoval, PM, Taravati, K, Tsai, K, Nosrati, A, Nardo, L, Alvarado, MD, Algazi, AP, Pampaloni, MH, Lobach, IV, Hwang, J, Pierce, RH, Gratz, IK, Krummel, MF & Rosenblum, MD 2016, 'Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma', Journal of Clinical Investigation, vol. 126, no. 9, pp. 3447-3452. https://doi.org/10.1172/JCI87324
Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. Journal of Clinical Investigation. 2016 Sep 1;126(9):3447-3452. https://doi.org/10.1172/JCI87324
Daud, Adil I. ; Loo, Kimberly ; Pauli, Mariela L. ; Sanchez-Rodriguez, Robert ; Sandoval, Priscila Munoz ; Taravati, Keyon ; Tsai, Katy ; Nosrati, Adi ; Nardo, Lorenzo ; Alvarado, Michael D. ; Algazi, Alain P. ; Pampaloni, Miguel H. ; Lobach, Iryna V. ; Hwang, Jimmy ; Pierce, Robert H. ; Gratz, Iris K. ; Krummel, Matthew F. ; Rosenblum, Michael D. / Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. In: Journal of Clinical Investigation. 2016 ; Vol. 126, No. 9. pp. 3447-3452.
@article{f89f80138bdd44369ad37606ef5e42a2,
title = "Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma",
abstract = "BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS. We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS. Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS. Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.",
author = "Daud, {Adil I.} and Kimberly Loo and Pauli, {Mariela L.} and Robert Sanchez-Rodriguez and Sandoval, {Priscila Munoz} and Keyon Taravati and Katy Tsai and Adi Nosrati and Lorenzo Nardo and Alvarado, {Michael D.} and Algazi, {Alain P.} and Pampaloni, {Miguel H.} and Lobach, {Iryna V.} and Jimmy Hwang and Pierce, {Robert H.} and Gratz, {Iris K.} and Krummel, {Matthew F.} and Rosenblum, {Michael D.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1172/JCI87324",
language = "English (US)",
volume = "126",
pages = "3447--3452",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

TY - JOUR

T1 - Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma

AU - Daud, Adil I.

AU - Loo, Kimberly

AU - Pauli, Mariela L.

AU - Sanchez-Rodriguez, Robert

AU - Sandoval, Priscila Munoz

AU - Taravati, Keyon

AU - Tsai, Katy

AU - Nosrati, Adi

AU - Nardo, Lorenzo

AU - Alvarado, Michael D.

AU - Algazi, Alain P.

AU - Pampaloni, Miguel H.

AU - Lobach, Iryna V.

AU - Hwang, Jimmy

AU - Pierce, Robert H.

AU - Gratz, Iris K.

AU - Krummel, Matthew F.

AU - Rosenblum, Michael D.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS. We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS. Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS. Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.

AB - BACKGROUND. Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS. We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS. Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS. Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.

UR - http://www.scopus.com/inward/record.url?scp=84987819121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987819121&partnerID=8YFLogxK

U2 - 10.1172/JCI87324

DO - 10.1172/JCI87324

M3 - Article

C2 - 27525433

AN - SCOPUS:84987819121

VL - 126

SP - 3447

EP - 3452

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -